NXTC +220% premarket; Nextcure and avere Therapeutics announce merger to advance once-weekly oral il-23 therapy Nextcure - combined company
NXTC +220% premarket; Nextcure and avere Therapeutics announce merger to advance once-weekly oral il-23 therapy Nextcure - combined company to operate as avere Therapeutics, trade as avrx after merger in h2 2026 - And avere Therapeutics announce definitive all-stock merger agreement - Announces concurrent $320M private placement led by fairmount and hansoh - Stockholders to own 1.21%, avere stockholders 98.79% of combined company at closing - Avere to pay hansoh $120M upfront, up to $2.18B in milestones, plus royalties for avr-1 ex-china rights - Stockholders to receive cvr for 90% of net proceeds from pipeline monetization for two years post-closing - Andrew cheng to serve as CEO, President, and Chairman of combined company Nextcure Inc: combined company plans to operate under name avere Therapeutics
NXTC +220% premarket; Nextcure and avere Therapeutics announce merger to advance once-weekly oral il-23 therapy Nextcure - combined company to operate as avere Therapeutics, trade as avrx after merger in h2 2026 - And avere Therapeutics announce definitive all-stock merger agreement - Announces concurrent $320M private placement led by fairmount and hansoh - Stockholders to own 1.21%, avere stockholders 98.79% of combined company at closing - Avere to pay hansoh $120M upfront, up to $2.18B in milestones, plus royalties for avr-1 ex-china rights - Stockholders to receive cvr for 90% of net proceeds from pipeline monetization for two years post-closing - Andrew cheng to serve as CEO, President, and Chairman of combined company Nextcure Inc: combined company plans to operate under name avere Therapeutics